Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) inhibitor,
R935788 (R788), at a dose of 100 mg, orally, twice-a-day, and/or a dose of of 150 mg, orally,
once-a-day is effective in the treatment of Rheumatoid Arthrits in patients who have had an
inadequate clinical response to methotrexate.